Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05635708). This is a study registration, not published results. Lead sponsor: BeiGene. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 418 participants (ACTUAL). Conditions: Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer. Interventions: DRUG: Tislelizumab; DRUG: BGB-A445; DRUG: LBL-007; DRUG: Carboplatin; DRUG: Cisplatin; DRUG: pemetrexed; DRUG: Paclitaxel; DRUG: Nab paclitaxel; DRUG: BGB-15025. Primary outcome measures: Confirmed overall response rate (ORR) , Up to 6 months. Brief summary: The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).